Russia’s $30 Billion Pharma Market: IP Battlegrounds, Patent Cliffs, and the Sovereignty Trap
The Russian pharmaceutical market generated 2.85 trillion roubles in 2024 — but every dollar of that growth evaporated in currency […]
November 2025
The $28B CIS Generic Drug Market: IP Strategy, Regulatory Risk, and Biosimilar Opportunity Through 2030
The Commonwealth of Independent States pharmaceutical market is one of the last large generic drug markets where the rules are
Brazil’s $57B Pharma Market: The IP, Patent, and Competitive Intelligence Playbook
Brazil’s pharmaceutical sector has quietly become one of the most strategically interesting IP battlegrounds in the world. The country’s market
Brazil’s $57B Pharma Market: The IP, Patent, and Competitive Intelligence Playbook Read Post »
Navigating the Intellectual Property Minefield: A Strategic Guide to Mitigating Patent Litigation Risks in M&A Due Diligence
Why Pharma M&A Is Really a Patent Acquisition Business When AstraZeneca paid $39 billion for Alexion in 2021, it wasn’t
A Strategic Guide to Capitalizing on Patent Expiry, Generic Entry, and Product Reformulation
The patent cliff is measurable, foreseeable, and still consistently underestimated. Between 2025 and 2030, the U.S. pharmaceutical market will surrender
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out
A deep strategic analysis of Process Analytical Technology and Quality by Design as instruments of competitive differentiation, IP defense, cost
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out Read Post »
How Chemical Patent Non-Infringement Strategy Wins Drug Markets
The complete analytical guide for pharma IP teams, portfolio managers, and generic entrants: from claim construction and Markush deconstruction to
How Chemical Patent Non-Infringement Strategy Wins Drug Markets Read Post »
The Small Molecule’s Resurgence: A Deep-Dive Strategic Analysis of FDA Approval Trends, IP Valuation, and Portfolio Economics for Pharma and Biotech Investors
1. The Approval Data That Rewrites the Narrative The dominant story in pharma investment circles for the better part of
The Authorized Generic Gambit: How Brand Pharma Weaponizes Its Own Patent Expiry
By the time a blockbuster drug’s first Paragraph IV challenger is ready to launch, the brand manufacturer has often already
The Authorized Generic Gambit: How Brand Pharma Weaponizes Its Own Patent Expiry Read Post »
